Disease · MONDO_0018364
Comparisons in its trials50
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 50
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nintedanib vs Placebo: serious adverse events | 379 of 902 | 157 of 450 | 1,352 | NCT01015118 | Trial comparisons |
| Pazopanib vs Placebo: deaths from any cause | 3 of 477 | 0 of 461 | 938 | NCT00866697 | Trial comparisons |
| Pazopanib vs Placebo: serious adverse events | 121 of 477 | 51 of 461 | 938 | NCT00866697 | Trial comparisons |
| Arm I (Adjuvant Chemotherapy Suboptimally Debulked) vs Arm II (Neoadjuvant Chemotherapy): serious adverse events | 122 of 346 | 167 of 346 | 692 | NCT01167712 | Trial comparisons |
| Trabectedin + DOXIL vs DOXIL: deaths from any cause | 132 of 286 | 131 of 282 | 568 | NCT01846611 | Trial comparisons |
| Trabectedin + DOXIL vs DOXIL: serious adverse events | 118 of 286 | 58 of 282 | 568 | NCT01846611 | Trial comparisons |
| Sorafenib (Nexavar, BAY43-9006) vs Placebo: serious adverse events | 26 of 123 | 25 of 123 | 246 | NCT00791778 | Trial comparisons |
| Everolimus (RAD001) Plus Bevacizumab vs Placebo Plus Bevacizumab: Incidence of Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) | 43 of 75 | 20 of 75 | 150 | NCT00886691 | Trial comparisons |
| Everolimus (RAD001) Plus Bevacizumab vs Placebo Plus Bevacizumab: serious adverse events | 35 of 75 | 24 of 75 | 150 | NCT00886691 | Trial comparisons |
| Gemcitabine vs Gemcitabine + Pazopanib: Number of Participants With Adverse Events | 73 of 73 | 75 of 75 | 148 | NCT01610206 | Trial comparisons |
| Gemcitabine vs Gemcitabine + Pazopanib: deaths from any cause | 54 of 73 | 63 of 75 | 148 | NCT01610206 | Trial comparisons |
| Gemcitabine vs Gemcitabine + Pazopanib: serious adverse events | 20 of 73 | 63 of 75 | 148 | NCT01610206 | Trial comparisons |
| Pazopanib 800 Milligrams vs Placebo: Number of Participants With Any Grade 3 or 4 AE | 39 of 72 | 8 of 72 | 144 | NCT01227928 | Trial comparisons |
| Pazopanib 800 Milligrams vs Placebo: serious adverse events | 7 of 72 | 4 of 72 | 144 | NCT01227928 | Trial comparisons |
| Grp - 1 vs Grp - 2: serious adverse events | 3 of 67 | 1 of 69 | 136 | NCT00041080 | Trial comparisons |
| Arm I (Paclitaxel and Carboplatin) vs Arm II (Ruxolitinib, Paclitaxel, and Carboplatin): Number of Patients Who Have Total Gross Resection (Phase II) | 20 of 35 | 49 of 77 | 112 | NCT02713386 | Trial comparisons |
| Arm I (Paclitaxel and Carboplatin) vs Arm II (Ruxolitinib, Paclitaxel, and Carboplatin): Number of Participants With Complete Pathological Response (Phase II) | 0 of 35 | 1 of 77 | 112 | NCT02713386 | Trial comparisons |
| Arm I Bevacizumab vs Arm II Bevacizumab + Fosbretabulin: serious adverse events | 9 of 53 | 16 of 54 | 107 | NCT01305213 | Trial comparisons |
| Cabozantinib vs Paclitaxel: serious adverse events | 25 of 55 | 8 of 50 | 105 | NCT01716715 | Trial comparisons |
| Paclitaxel + Placebo vs Paclitaxel + Pazopanib: Adverse Events as Assessed by CTCAE v.4 | 18 of 50 | 45 of 52 | 102 | NCT01468909 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018364/comparisons